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Childhood and Adult Asthma: 
Phenotype- and Endotype-Based 
Biomarkers
Joy N. Eze and Samuel N. Uwaezuoke
Abstract
The concept of asthma has changed from that of a single disease entity to 
that of a heterogeneous disease comprising several phenotypes linked to specific 
endotypes. Recently, significant progress has been made in disease classification 
into phenotypes and biologically distinct variants (endotypes). Classification of 
patients into endotypes has led to precision medicine in which specific biomarkers 
and appropriate individualized treatments have now been identified. Despite the 
ongoing classification of disease endotypes, the presence or absence of a T-helper 2 
(Th2) molecular signature has resulted in the association of asthma endotypes with 
phenotypes so as to establish responders and non-responders to inhaled corticoste-
roid therapy. More importantly, biologic therapies predicated on disease endotypes 
may in future constitute a paradigm shift from the traditional pharmacologic 
treatments and lead to better prognosis in moderate-to-severe forms of the disease 
(in which they are presently used). This book chapter aims to discuss the current 
concepts on asthma classification and biomarker-based diagnosis.
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1. Introduction
Asthma represents one of the major childhood noncommunicable respiratory 
diseases worldwide [1]. Asthma is now seen as a complex heterogeneous disease 
with variable natural history, severity, comorbidities, and therapeutic response. The 
disease is thus defined in several ways. For instance, asthma is defined as an airway 
disorder with underlying chronic inflammation characterized by hyper-responsive 
airway, which results in nonspecific symptoms like recurrent wheezing, breathless-
ness, nocturnal or early morning cough, and chest tightness. The symptoms tend to 
change over time and intensity, in conjunction with variable airflow limitation [2]. 
The disease also represents a syndrome with several phenotypes (the observable 
physical characteristics from the gene–environment interactions) and endotypes 
[3]. Research within the last decade has sought to better understand the heteroge-
neous nature of asthma. Disease heterogeneity particularly manifests in the clinical 
features, as well as the type and degree of airway inflammation and remodeling. 
Thus, there is now a paradigm shift in the concept of asthma as a single disease 
entity to that of a complex cluster of disease phenotypes [4]. Various subtypes of 
inflammation and complex immunoregulatory pathways and the factors respon-
sible for their failure have now been documented.
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2. Asthma phenotypes and endotypes: A snapshot
An endotype is a subtype of a disease recognized by a characteristic patho-
physiologic mechanism, whereas a disease phenotype refers to any identifiable 
characteristic without any evidence of a mechanism [5]. Recent advances in asthma 
management have tried to group patients by a plethora of possible phenotypic 
features including age of onset, presence of atopy, airway inflammation and severity 
of airway obstruction, and the need for drugs. On the basis of the diverse cellular 
and molecular mechanisms, several phenotypes are currently recognized [6]. 
Using sputum cytological examination, there is now a classification of the major 
inflammatory phenotypes into eosinophilic, neutrophilic, mixed-complex inflam-
mation, and pauci-granulocytic phenotypes [7]. Other recognizable phenotypes 
include early-onset mild allergic asthma, late-onset asthma associated with obesity, 
and severe nonatopic asthma with frequent exacerbations [8]. Experts from the 
European Academy of Allergy and Clinical Immunology and the American Academy 
of Allergy, Asthma, and Immunology produced the PRACTALL (Practical Allergy) 
consensus report which proposed the use of parameters such as clinical features, bio-
markers, pulmonary physiology, genetics, histopathology, therapeutic response, and 
epidemiology for characterizing disease endotypes [9]. The consensus of opinion 
was that each endotype should meet at least five of these seven criteria [9].
3. Phenotype- and endotype-based biomarkers
Biomarkers are unique parameters linked to disease endotypes which are 
estimated for the evaluation of any biologic or pathogenic processes, including 
responses to therapeutic interventions [5]. Their use has made it possible for novel 
diagnostic tools and targeted therapies to be developed.
3.1 Phenotype-based inflammatory biomarkers
Several biomarkers are now veritable sources of information with respect to disease 
phenotypes and therapeutic responses. The major examples are described as follows:
3.1.1 Inflammatory cells
Marked blood eosinophilia has been linked to a severe form of late-onset 
asthma. In fact, blood or sputum eosinophilia is an indicator of Th2-type inflam-
mation in the lungs, while sputum eosinophilia is associated with exacerbations 
[10, 11] and airway remodeling in asthma [12, 13]. The actions of T-helper 2 (Th2) 
cells are believed to trigger the stimulation of eosinophilic infiltration into the 
airways. Eosinophils are made to evolve from an inactive state to a state of increased 
hyper-responsiveness by priming agents such as these cytokines, interleukin 
(IL)-3, IL-4, IL-5, and IL-13 [8], and granulocyte-monocyte colony-stimulating 
factor (GM-CSF) [14]. IL-4 and IL-13 upregulate vascular adhesion molecules and 
facilitate the migration of eosinophils into tissue sites of inflammation, while IL-5 
facilitates differentiation, survival, and chemotaxis of eosinophils [8, 13, 14].
3.1.2 Proteins
While Th2 cytokines can be assayed from bronchial washings, the approach may 
not be practicable. Proteins emanating from the bronchus which are linked to Th2 
airway inflammation are used as surrogate markers for disease phenotype and endo-
type. Three genes upregulated by Th2 cytokines (IL-13) have been identified, namely, 
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POSTN, which encodes periostin; CLCA1, which encodes calcium-activated chloride 
channel regulator 1; and SERPINB2, which encodes serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 (serpinB2, also known as plasminogen activator inhibitor-2) 
[13]. Increased levels of these proteins correlate with higher amount of bronchial tis-
sue IL-13 and IL-5 messenger RNA and elevated number of eosinophils and mast cells. 
Blood levels of periostin have been studied as a surrogate marker for airway eosino-
philia and as a method for predicting response to pharmacologic IL-13 blockade with 
lebrikizumab and anti-IL-13 antibody. The findings of these proteins in subjects with 
high Th2 also correlate with better response to ICS therapy than Th2-low group. Thus, 
identification of these proteins is predictive of corticosteroid-responsive asthma.
3.1.3 Epithelial microRNAs
There is a high differential expression of microRNAs (miRNAs) in the air-
way epithelium of subjects with asthma as compared with healthy controls [15]. 
MicroRNAs have been identified as regulators of key biologic processes in epithelial 
cells such as cell proliferation, cell differentiation, and cell death [16, 17]. Woodruff 
et al. conducted in vitro experimentation with bronchial epithelial cells and 
observed that IL-13 had obvious effects on bronchial epithelial miRNA expression 
and that several of these changes underscored the differences between asthma and 
health that were seen in humans [13]. Subsequent work focused on constant in vivo 
and in vitro suppression of four members of the miR-34/449 family (miR-34c-5p, 
miR- 34c-5p, miR-449a, and miR-449b-5p) in asthma and by IL-13, respectively. 
These data lend credence to the possible biological role of the miR-34/449 family in 
airway epithelial cells. It is uncertain whether the potential regulation of miRNAs, 
or others by IL-13, can be an indicator of a high-Th2 asthma endotype. However, 
miRNAs possess a relatively distinct characteristic which may qualify them as poten-
tial biomarkers. In other words, miRNAs can assume forms in extracellular fluids 
which are resistant to breakdown by RNases and thus can be estimated in sputum, 
bronchoalveolar lavage fluid, and blood using PCR, microarrays, and sequencing 
methods [13]. The following proteins, miR-181a, miR- 146a, and miR-146b, are 
expressed in spleen CD41 T lymphocytes and probably function as proinflammatory 
agents in an animal model of asthma [18, 19]. Specifically, there was downregula-
tion of miR-375 in IL-13 transgenic mice and its repression in human bronchial 
(and esophageal) epithelial cells by IL-13 [20]. In addition, miRNA let-7 possesses a 
complex but proinflammatory activity in an animal model of the disease [21].
3.1.4 Exhaled nitric oxide (FeNO)
There is a moderate correlation between exhaled nitric oxide and bronchial 
or blood eosinophilia in asthmatics. The enzyme nitric oxide (NO) synthase that 
produces NO is under direct regulation of IL-13, which is a Th2 cytokine. Elevated 
FeNO level reflects increased IL-13 activity [22] and indicates the presence of Th2 
phenotype. The FeNO is a consistent predictor of a potential steroid responsiveness 
more than other indices (spirometry, airway hyper-responsiveness to methacholine, 
bronchodilator response, peak flow variation, etc.) [23].
3.2 Asthma endotypes and associated biomarkers
3.2.1 Allergic asthma
This is a form of persistent asthma which commences in the pediatric-age 
period. Sensitization to allergens and allergic rhinitis are prominent features. 
Inhalation of a specific allergen is a stimulus for the acute constriction of bronchial 
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smooth muscles and subsequent infiltration of inflammatory cells, usually followed 
by a late asthmatic presentation [9]. This condition is believed to be sustained by 
a Th2-dominant inflammation. Airway eosinophilia is a common feature, and the 
disease comprises a wide spectrum of disease severities and therapeutic responses. 
The explorations of IL-4/IL-13 pathway modifiers and the effectiveness of omali-
zumab in severe allergic asthma underscore the role of IgE and Th2 cells/cytokines 
in this endotype. Children with asthma predictive indices (API) are susceptible to 
developing asthma and may or may not include the classic”allergic asthma endo-
type.” The API include presentation with recurrent wheezing episodes (more than 
three episodes in the first 3 years of life) and at least one of the three major criteria 
(personal atopic dermatitis, parental asthma, or sensitization to an aeroallergen) or 
two of the three minor criteria (peripheral eosinophils >4%, wheezing unrelated to 
the common cold, or sensitization to a food allergen) [24, 25]. Patients who fulfilled 
these criteria at 3 years of age are clearly at increased risk of manifesting with active 
asthma symptoms at 6 years of age [9, 25].
3.2.2 Allergic bronchopulmonary mycosis (ABPM)
This condition develops in adults with asthma or in adult/pediatric patients with 
cystic fibrosis [26]. It is characterized by hypersensitivity reaction to airway coloni-
zation by molds, especially Aspergillus fumigatus [9, 26]. The main histological fea-
ture of ABPM is allergic (eosinophilic) mucin-harboring hyphae in the bronchi, as 
the induction of the formation of eosinophilic extracellular DNA cell death (ETosis) 
by viable fungi remains vital [26]. Clinically, ABPM is characterized by episodic 
bronchial obstruction and mucoid impaction, peripheral blood eosinophilia, 
elevated serum IgE levels, IgE and IgG antibodies specific for fungi, and typical 
radiographic findings [9, 26]. A mixed picture of neutrophilic and eosinophilic 
airway inflammation has also been described [9]. This endotype is characterized by 
severe bronchial asthma with recurrent exacerbations and progressive lung damage 
but may respond to systemic glucocorticoids, antifungal agents, and the anti-IgE 
monoclonal antibody (mAb), omalizumab [9, 26]. Patients develop bronchiectasis 
and fixed airflow obstruction over time. Early-onset ABPM may be a sequela of the 
allergic asthma endotype or cystic fibrosis [9].
3.2.3 Aspirin-sensitive asthma (ASA)
It almost always appears in adulthood and has a distinct clinical presentation, 
presenting after the intake of a nonsteroidal anti-inflammatory drug (NSAID)  
[9, 27]. Severe and prolonged airway obstruction is characteristically associated 
with chronic/severe rhinosinusitis and nasal polyps (aspirin-exacerbated respira-
tory disease), peripheral blood eosinophilia, and raised urinary leukotrienes at 
baseline and post-aspirin challenge. Pathophysiologically, ASA has been linked to 
increased elaboration of cysteinyl leukotriene and increased expression of leukot-
riene C4 synthase. Cysteinyl leukotriene receptor antagonists and leukotriene C4 
synthesis inhibitors ameliorate ASA symptoms although these medications do not 
protect the patient from NSAID adverse effects [28].
A subgroup of individuals with late-onset asthma in adulthood fulfills the criteria 
for a distinctive asthma endotype. They constitute about 20% of patients grouped as 
having refractory asthma and exhibit a typical pattern of severe exacerbations which 
are circumvented by systemic corticosteroid but not ICS, as well as hyper-eosinophilia 
in the blood (>1000/mm3) and sputum (>10%) [29]. These patients also have a lower 
prevalence of atopy than the “allergic asthma” endotype [9]. Moreover, the degrees of 
bronchodilator responsiveness and nonspecific airway hyper-responsiveness may be 
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less than those in the “allergic asthma” endotype. Studies have suggested that anti-
IL-5 therapy may also be effective in this endotype [30, 31].
3.2.4 Cross-country skiers’ asthma
It is defined as episodes of asthma symptoms and/or wheeze closely associated 
with strenuous skiing-related exercise and concomitant airway hyper-responsive-
ness. An extremely cold, dry climate promotes the evolution of this type of asthma 
in comparison with warmer, more humid conditions [32, 33]. Cross-country skiers’ 
asthma is rarely associated with allergic sensitization but is characterized by airway 
inflammation dominated by elevated numbers of lymphocytes, macrophages, and 
neutrophils but rarely eosinophils. Lymphoid aggregates in the form of bronchus-
associated lymphoid tissue in the mucosa, as well as evidence of airway remodeling 
with thickening of the reticuloepithelial membrane can be identified in broncho-
scopic studies.
Amateur endurance runners had an elevated number of bronchial epithelial cells 
and apoptosis of bronchial cells in induced sputum evolving through repeated half-
marathon races, in addition to increased serum levels of CC16 and raised superna-
tant interleukin (IL)-8 levels in induced sputum [34]. Furthermore, urinary levels of 
CC16 are increased following exercise [35, 36]. Increased expression as measured by 
polymerase chain reaction (PCR) of the gel-forming mucin, MUC5AC, in induced 
sputum and levels of supernatant cysteinyl leukotrienes and higher ratio of cysteinyl 
leukotrienes to prostaglandins have been reported. This endotype is resistant to ICS 
therapy, but its symptoms often improve with a drop in intensity of training.
Phenotype Eosinophilic asthma
Endotypes: allergic asthma (adult)*, aspirin-sensitive asthma, severe late-onset hyper-
eosinophilic asthma*, ABPM*
Phenotype Exacerbation-prone asthma
Endotypes: allergic asthma (adult)*, aspirin-sensitive asthma*, late-onset hyper-eosinophilic 
asthma, API-positive preschool wheezers*, ABPM*, viral-exacerbated asthma, premenstrual 
asthma
Phenotype Obesity-related asthma
Endotypes: airflow obstruction caused by obesity, severe steroid-dependent asthma, severe 
late-onset hyper-eosinophilic asthma*
Phenotype Exercise-induced asthma
Endotypes: cross-country skiers’ asthma, other forms of elite-athlete asthma, allergic 
asthma, API-positive preschool wheezers*
Phenotype Adult-onset asthma
Endotypes: aspirin-sensitive asthma*, infection-induced asthma, severe late-onset hyper-
eosinophilic asthma*
Phenotype Fixed airflow limitation
Endotypes: noneosinophilic (neutrophilic) asthma
Phenotype Poorly steroid-responsive asthma
Endotypes: noneosinophilic (neutrophilic) asthma, steroid-insensitive eosinophilic asthma, 
airflow obstruction caused by obesity
Culled from [9].
*NB: asthma phenotypes can be present in more than 1 endotypes and endotypes can contain more than 1 phenotype.
Table 1. 
Proposed relationship between asthma phenotypes and endotypes.
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Endotypes Biomarkers
Asthma predictive index preschool 
wheezers
>4% eosinophil in blood (minor), aeroallergen-specific IgE
Allergic asthma (adults) Positive SPT, elevated IgE/elevated FeNO
Severe late-onset hyper-eosinophilic asthma Peripheral blood eosinophilia
Allergic bronchopulmonary mycosis 
(ABPM)
Blood eosinophilia, markedly elevated IgE and specific IgE
Aspirin-sensitive asthma Blood eosinophilia, increased urinary LTEs
Cross-country skiers’ asthma FeNO normal, normal blood eosinophil count, increased 
urinary LTEs
SPT, skin prick test; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; LTEs, leukotrienes.
Table 2. 
Biomarkers associated with some endotypes.
Obviously, the pathophysiologic mechanisms underlying the various asthma 
phenotypes and endotypes are diverse. Thus, the biomarkers of these phenotypes 
and endotypes are different but may be interwoven since phenotypes may be linked 
with more than one endotype and vice versa. Table 1 shows the possible relation-
ship between asthma phenotypes and endotypes, while Table 2 shows some of the 
biomarkers associated with disease endotypes.
4. Conclusion
The pathogenic concept of asthma in childhood and adulthood is changing. Its 
current concept is that of a heterogeneous and genetically complex disease with 
several phenotypes presenting with distinct clinical features which are linked to 
endotypes with different underlying mechanisms and characteristic therapeutic 
responses. More importantly, the categorization of endotypes in childhood asthma 
is still evolving as disease classification has now been able to associate phenotypes 
with endotypes based on airway and serum biomarkers. Better still, there is a 
potential nexus between disease phenotypes and endotypes or biomarkers, as well 
as some potential personalized therapeutic options. In the future, endotypes may be 
used together with specific biomarkers to predict responses to targeted treatments.
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